{ }
Asian shares showed mixed results as markets awaited U.S. personal spending data. Japan's core inflation rose to 2.7%, prompting a stronger dollar against the yen. Meanwhile, U.S. markets faced volatility, with the S&P 500 still on track for a strong year despite recent fluctuations.
Asian shares showed mixed results as markets awaited U.S. personal spending data. Japan's core inflation rose to 2.7% year-on-year, prompting the dollar to strengthen against the yen. Meanwhile, the S&P 500 remains on track for a strong year despite recent market struggles, with traders adjusting expectations for future interest rate cuts by the Federal Reserve.
U.S. markets are set to open lower as a potential government shutdown looms, following the House's rejection of President-elect Trump's funding plan. Futures for the S&P 500 and Dow Jones fell, while FedEx shares surged 9% after exceeding profit expectations. In Europe, major indices declined, and Japan's inflation data exceeded forecasts, impacting the yen's value.
Asian shares showed mixed results as markets awaited U.S. personal spending data. Japan's core inflation rose to 2.7% year-on-year, prompting the dollar to strengthen against the yen. Meanwhile, U.S. Treasury yields fluctuated amid mixed economic reports, with the S&P 500 still on track for a strong year despite recent market struggles.
Micron Technology, Inc. focuses on semiconductor development, manufacturing, and marketing, with a diverse product range including dynamic and flash memory. As of August 31, 2023, net sales are primarily driven by IT infrastructure (36.7%) and mobile devices (23.4%), with significant geographic distribution in the U.S. (50.2%) and Taiwan (17.4%). The company operates 11 production sites globally.
Micron Technology, Inc. focuses on designing, manufacturing, and marketing semiconductors, including dynamic and flash memory products. Its sales are primarily driven by IT infrastructure (36.7%), mobile devices (23.4%), and storage media (16.4%), with a global presence across 11 production sites. The company generates 50.2% of its sales in the United States, followed by Taiwan (17.4%) and China (14%).
Asian indices are set for a mixed open following a hawkish Federal Reserve outlook, with the Nikkei 225 up 0.32% while the ASX 200 and KOSPI decline by 1.12% and 1.28%, respectively. Key economic data, including China's loan prime rate decision and upcoming U.S. core PCE price data, will be closely monitored as they may influence market sentiment and Treasury yields. The ASX 200 is testing support levels, while the Singapore Blue Chip index shows signs of bearish divergence, and the China A50 remains range-bound amid policy uncertainty.
IG
The Global Uveitis Treatment market is projected to grow from USD 725 million in 2024 to USD 1.28 billion by 2032, with a CAGR of 8.5%. The study covers various treatment types, including corticosteroids and biologic agents, and offers customization options for regional and application-specific analysis. Key players include Novartis, Pfizer, and AbbVie, with North America leading the market and Asia-Pacific identified as the fastest-growing region.
Cryptocurrency theft surged to $2.2 billion in 2024, with North Korean hackers responsible for 61% of the losses, totaling $1.34 billion across 47 incidents. While decentralized finance platforms were primary targets in early 2024, the focus shifted to centralized services later in the year, highlighted by significant breaches at DMM Bitcoin and WazirX. The ongoing threat from these cybercriminals emphasizes the urgent need for enhanced security measures in the crypto industry.
Xcovery Holdings' ensartinib, branded as Ensacove, has received FDA approval as a first-line treatment for ALK-positive non-small cell lung cancer, marking a significant milestone as the first innovative targeted lung cancer drug from a Chinese company to enter the U.S. market. While it shows a 44% reduction in progression or death compared to Pfizer's Xalkori, it faces stiff competition from established ALK inhibitors like Roche's Alecensa, which has demonstrated superior efficacy in previous studies. Despite its potential, Ensacove's market entry comes amid a landscape dominated by major pharmaceutical players.
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.